R&D | February 04, 2026
Epigenica launches EpiFinder Analysis Service to accelerate Epigenomic research
The new service delivers end-to-end support, managing every stage of an epigenomics project
The new service delivers end-to-end support, managing every stage of an epigenomics project
The approval follows the pivotal Phase III ARANOTE trial, which demonstrated that darolutamide plus ADT cut the risk of radiological progression or death by 46% compared to placebo plus ADT
The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period
The approved Lacosamide Oral Solution is bioequivalent and therapeutically equivalent to the reference drug and will be manufactured at Indoco’s facility in Verna Industrial Area, Goa
A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
The base Gland business posted ?11,790 million in revenue, up 16% YoY
Subscribe To Our Newsletter & Stay Updated
